chartexchange

GH Research Announces Appointment of Vanina Popova, MD, as Chief Development Officer

GlobeNewswire Inc. | Nov 13, 2026 7:55 AM EST

DUBLIN, Nov. 13, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the appointment of Vanina Popova, MD, as Chief Development Officer, to lead the clinical development of GH001 into our pivotal programs in treatment-resistant depression (TRD) and postpartum depression (PPD).

Read original article